Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1 4Phase 4 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 8OTHER_GOV 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Polycystic Ovary Syndrome 1

Interventions

Bevacizumab 4Zoledronic Acid 3Cisplatin 3Capecitabine 3spartalizumab 2anlotinib 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Metformin 2Letrozole 2Drug Therapy 2vosaroxin 1venetoclax 1tislelizumab 1pembrolizumab 1enzalutamide 1empagliflozin 1atezolizumab 1apatinib 1abiraterone 1XELOX 1Vacuum Curettage 1Tyrosine Kinase Inhibitors 1Tuberculin 1Sorafenib 1Sodium Chloride 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Metformin × Clear all
NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

NCT03008551 2019-07-15

Empagliflozin vs Metformin in PCOS

Hull University Teaching Hospitals NHS Trust

Phase 2/3 Completed
40 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡